131 related articles for article (PubMed ID: 32402752)
1. Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate vaccine.
Kaur R; Pichichero M
Vaccine; 2020 Jun; 38(28):4423-4431. PubMed ID: 32402752
[TBL] [Abstract][Full Text] [Related]
2. Dose-specific Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children.
Lewnard JA; Givon-Lavi N; Dagan R
Clin Infect Dis; 2020 Nov; 71(8):e289-e300. PubMed ID: 31784753
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.
Spijkerman J; Veenhoven RH; Wijmenga-Monsuur AJ; Elberse KE; van Gageldonk PG; Knol MJ; de Melker HE; Sanders EA; Schouls LM; Berbers GA
JAMA; 2013 Sep; 310(9):930-7. PubMed ID: 24002279
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
[TBL] [Abstract][Full Text] [Related]
6. Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine.
Zimmermann P; Perrett KP; Berbers G; Curtis N
Arch Dis Child; 2019 Jul; 104(7):680-684. PubMed ID: 30796020
[TBL] [Abstract][Full Text] [Related]
7. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
10. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
Dagan R; Givon-Lavi N; Porat N; Greenberg D
Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
[TBL] [Abstract][Full Text] [Related]
11. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis.
Scott P; Rutjes AW; Bermetz L; Robert N; Scott S; Lourenço T; Egger M; Low N
Vaccine; 2011 Dec; 29(52):9711-21. PubMed ID: 21821080
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.
Chen JJ; Yuan L; Huang Z; Shi NM; Zhao YL; Xia SL; Li GH; Li RC; Li YP; Yang SY; Xia JL
BMJ Open; 2016 Oct; 6(10):e012488. PubMed ID: 27798013
[TBL] [Abstract][Full Text] [Related]
13. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
Cooper D; Yu X; Sidhu M; Nahm MH; Fernsten P; Jansen KU
Vaccine; 2011 Sep; 29(41):7207-11. PubMed ID: 21689707
[TBL] [Abstract][Full Text] [Related]
14. Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix
Kawade A; Dayma G; Apte A; Telang N; Satpute M; Pearce E; Roalfe L; Patil R; Wang Y; Noori N; Gondhali A; Juvekar S; Oron AP; Sanghavi S; Goldblatt D; Dagan R; Bavdekar A
Vaccine; 2023 May; 41(19):3066-3079. PubMed ID: 37045679
[TBL] [Abstract][Full Text] [Related]
15. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
[TBL] [Abstract][Full Text] [Related]
16. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.
Simell B; Nurkka A; Ekström N; Givon-Lavi N; Käyhty H; Dagan R
Clin Vaccine Immunol; 2012 Oct; 19(10):1618-23. PubMed ID: 22875604
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age.
Vesikari T; Karvonen A; Korhonen T; Karppa T; Sadeharju K; Fanic A; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2011 Aug; 30(8):e130-41. PubMed ID: 21540760
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.
Goldblatt D; Southern J; Andrews NJ; Burbidge P; Partington J; Roalfe L; Valente Pinto M; Thalasselis V; Plested E; Richardson H; Snape MD; Miller E
Lancet Infect Dis; 2018 Feb; 18(2):171-179. PubMed ID: 29174323
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial.
Kandasamy R; Gurung M; Thorson S; Yu LM; Galal U; Voysey M; Kelly S; Wahl B; Berbers G; Finnegan K; Ansari I; Paudel K; Murdoch DR; O'Brien KL; Kelly DF; Goldblatt D; Shrestha S; Pollard AJ
Lancet Infect Dis; 2019 Feb; 19(2):156-164. PubMed ID: 30635252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
